Literature DB >> 16249854

Pleomorphic carcinoma of the lung with mediastinal extension following malignant lymphoma: report of a case.

Takahiro Nakajima1, Toshihiko Iizasa, Akira Iyoda, Kenzo Hiroshima, Kazuhiro Yasufuku, Masako Chiyo, Takashi Anayama, Hidemi Suzuki, Kiyoshi Shibuya, Hidemi Ohwada, Takehiko Fujisawa.   

Abstract

In following up a patient with non-Hodgkin's lymphoma, we encountered a case of pulmonary pleomorphic carcinoma with mediastinal direct invasion. A 65-year-old man with hemoptysis was found to have an abnormal shadow in the right upper lung field. A 6.4 x 4.8-cm tumor adjacent to the upper mediastinum occupied the right anterior segment of the upper lobe (S3) and invaded the superior vena cava (SVC). The serum level of neuron-specific enolase was elevated to 11.9 ng/ml. A specimen from a transbronchial lung biopsy of the right B3b bronchus revealed giant tumor cells. A right upper lobectomy with SVC reconstruction was performed. The resected tumor was diagnosed as a pulmonary pleomorphic carcinoma with a large component of giant and spindle cells, and it is considered to be a rare histologic type.

Entities:  

Mesh:

Year:  2005        PMID: 16249854     DOI: 10.1007/s00595-005-3028-1

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  13 in total

1.  Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment.

Authors:  A J Swerdlow; M J Schoemaker; R Allerton; A Horwich; J A Barber; D Cunningham; T A Lister; A Z Rohatiner; G Vaughan Hudson; M V Williams; D C Linch
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

2.  Extended resections for bronchogenic carcinoma invading the superior vena cava system.

Authors:  L Spaggiari; J F Regnard; P Magdeleinat; B Jauffret; P Puyo; P Levasseur
Journal:  Ann Thorac Surg       Date:  2000-01       Impact factor: 4.330

3.  Analysis of the risk of solid tumor following Hodgkin's disease.

Authors:  R Maurizi Enrici; A P Anselmo; M F Osti; M Santoro; V Tombolini; F Mandelli; C Biagini
Journal:  Haematologica       Date:  1997 Jan-Feb       Impact factor: 9.941

4.  Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma.

Authors:  Y L Chang; Y C Lee; J Y Shih; C T Wu
Journal:  Lung Cancer       Date:  2001-10       Impact factor: 5.705

5.  Second primary cancer due to radiotherapy and chemotherapy.

Authors:  O Manavoğlu; B Orhan; T Evrensel; Y Karabulut; V Ozkocaman; C Ozyardimci
Journal:  J Environ Pathol Toxicol Oncol       Date:  1996       Impact factor: 3.567

6.  Second cancers following non-Hodgkin's lymphoma.

Authors:  L B Travis; R E Curtis; J D Boice; B F Hankey; J F Fraumeni
Journal:  Cancer       Date:  1991-04-01       Impact factor: 6.860

7.  Second lung adenocarcinoma after combination chemotherapy in two patients with primary non-Hodgkin's lymphoma.

Authors:  T Yamada; K Shinohara; K Takeda; N Kameda; K Katsuki; K Ariyoshi; T Kamei
Journal:  Jpn J Clin Oncol       Date:  1999-04       Impact factor: 3.019

8.  Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station.

Authors:  Y Ichinose; H Kato; T Koike; R Tsuchiya; T Fujisawa; N Shimizu; Y Watanabe; T Mitsudomi; M Yoshimura; M Tsuboi
Journal:  J Thorac Cardiovasc Surg       Date:  2001-10       Impact factor: 5.209

9.  Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease.

Authors:  F E van Leeuwen; R Somers; B G Taal; P van Heerde; B Coster; T Dozeman; S J Huisman; A A Hart
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

10.  Lung cancer following Hodgkin's disease: a case-control study.

Authors:  J M Kaldor; N E Day; J Bell; E A Clarke; F Langmark; S Karjalainen; P Band; D Pedersen; W Choi; V Blair
Journal:  Int J Cancer       Date:  1992-11-11       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.